Table 2.
Sorafenib treatment parameters
| Sorafenib (n=58) | Combination Tx (n=22) | p-value | |
|---|---|---|---|
| Starting dose 800 mg/day | 52 (89.6) | 21 (95.4) | 0.37 |
| Duration of sorafenib (days) | 66 | 367 | ⩽0.001 |
| Average dose (mg/day) | 495 | 488 | 0.86 |
| Combination with TACE | 0 | 13 (59.1) | NE |
| Combination with HAIC | 0 | 14 (63.6) | NE |
| Cessation of sorafenib | 52 (89.6) | 19 (86.4) | 0.47 |
| Disease progression | 27 (51.9) | 13 (68.4) | 0.16 |
| Adverse events | 25 (48.1) | 6 (31.6) | 0.17 |
| Tumor response: CR/PR/SD/PD/NE | 1/4/25/24/4 | 0/3/16/3/0 | NE |
| Objective response rate | 5 (9.3) | 3 (13.6) | 0.42 |
| DCR | 30 (51.7) | 19 (86.3) | 0.01 |
| Posttreatment (present) | 32 (55.1) | 8 (36.3) | 0.11 |
Note: Results reported as number or number (%).
Abbreviations: Tx, therapy; TACE, transarterial chemoembolization; HAIC, hepatic arterial infusion chemotherapy; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not examined; DCR, disease control rate.